EA202090922A1 - Композиции и способы истощения cd2+ клеток - Google Patents

Композиции и способы истощения cd2+ клеток

Info

Publication number
EA202090922A1
EA202090922A1 EA202090922A EA202090922A EA202090922A1 EA 202090922 A1 EA202090922 A1 EA 202090922A1 EA 202090922 A EA202090922 A EA 202090922A EA 202090922 A EA202090922 A EA 202090922A EA 202090922 A1 EA202090922 A1 EA 202090922A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
compositions
draining
methods
stem cell
Prior art date
Application number
EA202090922A
Other languages
English (en)
Inventor
Энтони Бойтано
Майкл Кук
Рахул Палчаудхури
Шон Макдонау
Original Assignee
Маджента Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Маджента Терапьютикс, Инк. filed Critical Маджента Терапьютикс, Инк.
Publication of EA202090922A1 publication Critical patent/EA202090922A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к анти-CD2-антителам, их антигенсвязывающим фрагментам и их конъюгатам антитело-лекарственное средство для применения в качестве агентов для лечения расстройства стволовых клеток, рака или аутоиммунного заболевания, среди других гематологических и пролиферативных заболеваний. Описанные здесь композиции и способы могут быть использованы для истощения популяций CD2+ клеток, таких как CD2+ раковые клетки и CD2+ иммунные клетки, и могут быть использованы для подготовки пациента к трансплантации гемопоэтических стволовых клеток.
EA202090922A 2017-11-29 2018-11-29 Композиции и способы истощения cd2+ клеток EA202090922A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592169P 2017-11-29 2017-11-29
PCT/US2018/063171 WO2019108860A1 (en) 2017-11-29 2018-11-29 Compositions and methods for the depletion of cd2+ cells

Publications (1)

Publication Number Publication Date
EA202090922A1 true EA202090922A1 (ru) 2021-03-09

Family

ID=66664617

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090922A EA202090922A1 (ru) 2017-11-29 2018-11-29 Композиции и способы истощения cd2+ клеток

Country Status (14)

Country Link
US (1) US20200368363A1 (ru)
EP (1) EP3717519A4 (ru)
JP (1) JP2021504414A (ru)
KR (1) KR20200090801A (ru)
CN (1) CN111670200A (ru)
AU (1) AU2018374282A1 (ru)
BR (1) BR112020010816A2 (ru)
CA (1) CA3082166A1 (ru)
CO (1) CO2020006855A2 (ru)
EA (1) EA202090922A1 (ru)
IL (1) IL274817A (ru)
MX (1) MX2020004806A (ru)
SG (1) SG11202004192XA (ru)
WO (1) WO2019108860A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021530545A (ja) * 2018-07-23 2021-11-11 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−ｃｄ２抗体薬物コンジュゲート（ａｄｃ）の使用
WO2021259927A2 (en) * 2020-06-23 2021-12-30 Zelarion Malta Limited Anti-cd2 antibodies
WO2022027052A1 (en) * 2020-07-28 2022-02-03 Northwestern University Clotrimazole as a treatment for immunodeficiency disorders
WO2023224980A1 (en) * 2022-05-17 2023-11-23 The Uab Research Foundation Methods and compositions for treating or preventing inflammatory skin disorders
WO2024079046A1 (en) * 2022-10-10 2024-04-18 Zelarion Malta Limited Anti-cd2 antibodies for type 1 diabetes
WO2024118559A2 (en) * 2022-11-28 2024-06-06 Icell Gene Therapeutics Inc. Engineered immune cells for treating disorders, compositions and methods thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592006B1 (en) * 1993-03-05 2009-09-22 Université Catholique de Louvain Composition comprising the LO-CD2a antibody
CA2157500C (en) * 1993-03-05 2005-08-16 Herve Bazin Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
US6849258B1 (en) * 1997-07-18 2005-02-01 Universite Catholique De Louvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
JP4808841B2 (ja) * 1997-07-18 2011-11-02 バイオトランスプラント，インコーポレイテッド Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその使用法
CA2309919A1 (en) * 1997-11-14 1999-05-27 The General Hospital Corporation Treatment of hematologic disorders
HUE027549T2 (hu) * 2002-07-31 2016-10-28 Seattle Genetics Inc Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
JP6321687B2 (ja) * 2014-03-10 2018-05-09 ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング アマトキシン誘導体
CA2966005C (en) * 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
WO2015151079A2 (en) * 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Auristatin analogues and their conjugates with cell-binding molecules
EP3958908A1 (en) * 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin antibody-drug conjugates and uses thereof

Also Published As

Publication number Publication date
EP3717519A4 (en) 2021-08-25
IL274817A (en) 2020-07-30
CO2020006855A2 (es) 2020-08-31
BR112020010816A2 (pt) 2020-11-10
EP3717519A1 (en) 2020-10-07
WO2019108860A1 (en) 2019-06-06
MX2020004806A (es) 2020-10-07
AU2018374282A1 (en) 2020-06-04
SG11202004192XA (en) 2020-06-29
KR20200090801A (ko) 2020-07-29
US20200368363A1 (en) 2020-11-26
WO2019108860A4 (en) 2019-08-01
JP2021504414A (ja) 2021-02-15
CA3082166A1 (en) 2019-06-06
CN111670200A (zh) 2020-09-15

Similar Documents

Publication Publication Date Title
EA202090922A1 (ru) Композиции и способы истощения cd2+ клеток
MX2018015684A (es) Composiciones y metodos para el agotamiento de celulas cd117.
MX2018015683A (es) Composiciones y métodos para el agotamiento de células.
WO2019084057A3 (en) Compositions and methods for the depletion of cd117+ cells
PH12015501493A1 (en) Anti-pdgfr-beta antibodies and uses thereof
EA201991692A1 (ru) Иммуносконструированные плюрипотентные клетки
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2022011546A (es) Composiciones y metodos para el agotamiento de celulas cd137+.
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PE20211786A1 (es) Anticuerpos humanizados contra c-kit
WO2019084064A3 (en) Compositions and methods for the depletion of cd117+ cells
EA202090947A1 (ru) Композиции и способы для истощения cd5+ клеток
EA201600190A1 (ru) Анти-prlr антитела и их применение
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
MX2021007848A (es) Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
EA202193309A1 (ru) Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
EA201790883A1 (ru) Толерогенные дендритные клетки, способы их получения и их применения
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
MX2022001007A (es) Inmunoterapia para poliomavirus.
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
JOP20190101A1 (ar) أنظمة علاج
WO2019173780A3 (en) Anti-cd252 antibodies, conjugates, and methods of use